^
Association details:
| Biomarker: | HER-2 mutation |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Aidixi (disitamab vedotin) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Matched therapies for advanced gastric cancer based on genotype: A real-world study in China.
Published date:
05/19/2021
Excerpt:
...9 (30%) harbored HER2 mutation/overexpression (received RC48-ADC or trastuzumab, cohort B)…In cohort B, ORR was 44% (4/9), DCR was 78% (7/9), mPFS and mOS was 3.1 months and 5.5 months, respectively.
DOI:
10.1200/JCO.2021.39.15_suppl.e16098
